



March 5, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Joint Research Agreement with Nagoya University for Spinal Cord Injury

Tokyo, March 5, 2020 – Gene Techno Science Co., Ltd. (“GTS”) executed a joint research agreement (“this agreement”) with Nagoya University for a development of new therapy for spinal cord injury.

1. Purpose of this agreement

Spinal cord injury is a motor and sensory dysfunction due to central nerve damages in the spinal cord mainly caused by traffic or sport accidents. Since the self-regeneration capacity of central nerves is extremely lower than that of peripheral nerves, patients with spinal cord injury have to live with life-long disabilities such as walking difficulty and sensory paralysis. As the functional recovery achieved by rehabilitation is limited, the development of new therapy has been long-awaited. Stem cell therapy is considered as a promising candidate and many research results have been reported. In particular, stem cells from human exfoliated deciduous teeth (“SHED”) have excellent capabilities of neuronal protection and regeneration which could prevent functional declines or restore neuronal functions in spinal cord injury.

Department of Neurosurgery in Nagoya University Hospital has a wealth of surgery record in various spinal cord diseases including spinal cord injury. In addition, it has strenuously advanced basic research on the neuronal regeneration and achieved significant research results. GTS and Nagoya University agreed on the potential utility of SHED for a new therapy of spinal cord injury, resulting in this joint research agreement.

2. Outline of counterparty to this agreement

1. Name	Nagoya University Hospital
2. Location	65 Tsurumai-cho, Showa-ku, Nagoya
3. Hospital Director	Yasuhiro Kodera
4. Department	Neurosurgery

3. Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com